GPCM
INMB icon

Granite Point Capital Management’s INmune Bio INMB Stock Holding History

Granite Point Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250,000
Closed -$2.58M – 177
2020
Q3 		$2.58M Buy
+250,000
New +$2.54M 0.14% 80

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAIM
Financial Advocates Investment Management Olympia, Washington $178M AUM 21.03% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Granite Point Capital Management's INMB Position: Q4 2020 in Review

Granite Point Capital Management sold out of INmune Bio (INMB) in Q4 2020, closing a stake of 250,000 shares — an estimated $2.58M sold.

Granite Point Capital Management first reported a position in INMB in Q3 2020 and held it in 1 quarter. The position peaked at $2.58M in Q3 2020. 26 funds tracked by Wall St. Rank hold INMB as of Q4 2020.

  • Granite Point Capital Management reported no remaining INmune Bio position as of Q4 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 250,000 INmune Bio shares in Q4 2020, an estimated $2.58M.
  • Granite Point Capital Management first reported a position in INmune Bio in Q3 2020 and held it in 1 quarter.
  • Granite Point Capital Management's INmune Bio position peaked at $2.58M in Q3 2020.
  • 26 funds tracked by Wall St. Rank held INmune Bio as of Q4 2020.

Based on Granite Point Capital Management's 13F filing for Q4 2020, filed 5 Feb 2021.